Hear from Donna, a real LUTATHERA patient
Hear from Donna, a real LUTATHERA patient
“My local oncologist had suggested LUTATHERA as an option to slow the progression…This was the best long-term option for me”
I was recently diagnosed with GEP-NETs—can LUTATHERA be my first treatment?
Know your NETs: Understand what your recently diagnosed cancer looks like
Choosing the first treatment for your cancer is a big step after diagnosis. The questions below can help you and your doctor see if LUTATHERA could fit into your treatment plan right from the start.
Has my cancer spread to my lymph nodes or other organs?
LUTATHERA was studied in people who had GEP-NETs that spread to nearby tissue, lymph nodes, or other organs. People who couldn’t have surgery to remove their cancer were also included.
Is my cancer well-differentiated?
LUTATHERA was studied in people who had well-differentiated GEP-NETs.
Is my tumor functional (producing hormones) or nonfunctional?
LUTATHERA is an option for functional and nonfunctional tumors.
Is my cancer SSTR+?
LUTATHERA targets NET cells that have proteins called somatostatin receptors (SSTRs). You can find out if your cancer is SSTR positive (SSTR+) by asking your doctor to undergo SSTR imaging. You may have heard this referred to as a gallium or copper scan.
Is my cancer faster growing (Ki-67, 10% or more [grade 2 or 3])?
A Ki-67 test can tell you how fast your cancer is growing. LUTATHERA was studied in people who have faster-growing GEP-NETs (Ki-67, 10%–55% [grade 2 or 3]).
If these apply to your cancer, ask your doctor if LUTATHERA could be the right first treatment for you.
I am currently on an SSA—can LUTATHERA be my next step?
Know your NETs: Understand what your cancer looks like after SSA progression
If the SSA you’re taking now isn’t enough, or if your NETs progress in the future, it’s important to talk with your doctor about what to do next. The questions below can help you and your doctor decide on the right time to start LUTATHERA.
Is my cancer slower growing (Ki-67, 0%–20% [grade 1 or 2])?
A Ki-67 test can tell you how fast your cancer is growing. LUTATHERA was studied in people who have slower-growing GEP-NETs (Ki-67, 0%–20% [grade 1 or 2]).
Is my cancer progressing while on SSA treatment?
If your cancer grew or spread, SSA treatment may not be enough. LUTATHERA was studied in people whose cancer progressed while on SSA treatment.
Has my cancer spread to my lymph nodes or other organs?
LUTATHERA was studied in people who had GEP-NETs that spread to nearby tissue, lymph nodes, or other organs. People who couldn’t have surgery to remove their cancer were also included.
Has my doctor confirmed that my cancer is SSTR+?
LUTATHERA targets NET cells that have proteins called SSTRs. You can find out if your cancer is SSTR+ by asking your doctor to undergo SSTR imaging. You may have heard this referred to as a gallium or copper scan.
If these apply to your cancer, ask your doctor if LUTATHERA could be the right next step for you.
GEP-NETs, gastroenteropancreatic neuroendocrine tumors; NETs, neuroendocrine tumors; SSA, somatostatin analogue.